Ulusal Venöz Tromboembolizm Profilaksi ve Tedavi Kılavuzu 2010

122
46. American Academy of Orthopaedic Surgeons Board of Directors. American Academy
of Orthopaedic Surgeons Clinical Guideline on the Prevention of Symptomatic Pulmonary
Embolism in Patients Undergoing Total Hip or Knee Artroplasty. 2007.
47. TOTB‹D VTE De¤erlendirme Formu, www.totbid.org, 2010.
48. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, et al.
Randomized, placebo-controlled trial of dalteparin for the prevention of venous
thromboembolism in acutely ill medical patients. Circulation. 2004;110:874-879.
49. Samama MM, Cohen AT, Darmon J-Y, Desjardins L, Eldor A, Janbon C, et al. A
comparison of enoxaparin with placebo for the prevention of venous thromboembolism
in acutely ill medical patients. N Engl J Med 1999;341:793-800.
50. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al.
Fondaparinux for the prevention of VTE in acutely ill medical patients. Blood
2003;102:42A.
51. Haas SK. Venous thromboembolic risk and its prevention in hospitalized medical
patients. Semin Thromb Hemost 2002;28(6):577-584.
52. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al.
Efficacy and safety of fondaparinux for the prevention of venous thromboembolism
in older acute medical patients: randomised placebo controlled trial. BMJ
2006;332(7537):325-329.
53. NCCN Clinical Practice Guidelines in Oncology. Venous Thromboembolic Disease.
V.1.2010
54. Mandala M, Falanga A, Roila F. Venous thromboembolism in cancer patients:
ESMO Clinical Practice Guidelines for the management. Ann Oncol 2010;21 (Suppl
5):274-276.
55. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et
al. American Society of Clinical Oncology Guideline: Recommendations for venous
thromboembolism prophylaxis and treatment in patients with cancer. JCO 2007;25:5490-
5505.
56. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines
for the early management of adults with ischemic stroke (AHA/ASA guideline). Stroke
2007;38:1655-1711.
57. Elias A, Milandre L, Lagrange G, Aillaud MF, Alonzo B, Toulemonde F, et al.
Prevention of deep venous thrombosis of the leg by a very low molecular weight
heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a
randomized pilot study (30 patients). Rev Med Intern 1990;11:95-98.
58. Prins MH, Gelsema R, Sing AK, van Heerde LR, den Ottolander GJ. Prophylaxis of
deep venous thrombosis with a low-molecular-weight-heparin (Kabi 2165/Fragmin)
in stroke patients. Haemostasis 1989;19:245-250.
59. Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind
and randomized placebo-controlled trial of low molecular weight heparin once daily
to prevent deep-vein thrombosis in acute ischemic stroke. Semin Thromb Hemost
1990;16 Suppl:25-33.